BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33570184)

  • 21. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.
    Kimby E; Brandt L; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):224-30. PubMed ID: 11441934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
    Benjamini O; Jain P; Trinh L; Qiao W; Strom SS; Lerner S; Wang X; Burger J; Ferrajoli A; Kantarjian H; O'Brien S; Wierda W; Estrov Z; Keating M
    Leuk Lymphoma; 2015 Jun; 56(6):1643-50. PubMed ID: 25308294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
    Knauf WU; Lissitchkov T; Aldaoud A; Liberati AM; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Merkle K; Montillo M
    Br J Haematol; 2012 Oct; 159(1):67-77. PubMed ID: 22861163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
    Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
    Soini E; Hautala A; Poikonen E; Becker U; Kyttälä M; Martikainen J
    Clin Ther; 2016 Apr; 38(4):889-904.e14. PubMed ID: 26970696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
    Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
    Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
    Singh M; Mealing S; Baculea S; Cote S; Whelan J
    J Med Econ; 2017 Oct; 20(10):1066-1073. PubMed ID: 28720054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
    Robak T; Kasznicki M
    Leukemia; 2002 Jun; 16(6):1015-27. PubMed ID: 12040433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.
    Nemets A; Ben Dor D; Barry T; Ducach A; Blumental R; Ben Alon D; Lugassy G
    Leuk Lymphoma; 2003 Dec; 44(12):2151-4. PubMed ID: 14959863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
    Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.
    Lam CC; Ma ES; Kwong YL
    Am J Hematol; 2005 Aug; 79(4):288-90. PubMed ID: 16044456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fludarabine in chronic lymphocytic leukaemia.
    Elter T; Hallek M; Engert A
    Expert Opin Pharmacother; 2006 Aug; 7(12):1641-51. PubMed ID: 16872267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy.
    Callea V; Brugiatelli M; Stelitano C; Gentile M; Nobile F; Morabito F
    Leuk Lymphoma; 2006 Nov; 47(11):2314-20. PubMed ID: 17107903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia.
    Maung ZT; Wood AC; Jackson GH; Turner GE; Appleton AL; Hamilton PJ
    Br J Haematol; 1994 Nov; 88(3):649-52. PubMed ID: 7819085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia.
    Vainer N; Aarup K; Andersen MA; Wind-Hansen L; Nielsen T; Frederiksen H; Enggaard L; Poulsen CB; Niemann CU; Rotbain EC
    Br J Haematol; 2023 Jun; 201(5):874-886. PubMed ID: 36896699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with fludarabine in leukaemia.
    Keating MJ; Estey E; O'Brien S; Kantarjian H; Robertson LE; Plunkett W
    Drugs; 1994; 47 Suppl 6():39-49. PubMed ID: 7525188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
    Gordon MJ; Lewis LD; Brown JR; Danilov AV
    Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabine.
    Wells T; Kovacs MJ
    Ann Pharmacother; 2003 May; 37(5):671-4. PubMed ID: 12708944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.